Medgenics, Inc. Appoints Dr. Marvin Garovoy as Chief Medical Officer

Published: Aug 14, 2012

MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, is pleased to announce the appointment of Marvin Garovoy, M.D. as Chief Medical Officer. Dr. Garovoy is a transplant nephrologist, biotechnology executive and former university professor with experience in all stages of clinical development.

Back to news